Ultralife Corp Dossier - Source-backed chat

Ultralife Corp

ULBINASDAQ

SectorIndustrials

IndustryElectrical Components & Equipment

Beta (adjusted)0.85

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $6.46Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $107.6M

Enterprise Value $146.4M

Shares Outstanding 16.7M diluted

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Ultralife Corporation (ULBI) is navigating a transitional phase marked by near-term operational headwinds and margin compression, balanced by a robust demand outlook. In Q1 2026, the company reported a net loss of $0.03 per share, missing consensus estimates due to shipment delays, plant shutdowns, and non-recurring consulting/litigation costs. However, its record backlog of $115.1 million highlights strong underlying demand across defense, medical, and industrial channels. While the long-term growth trajectory remains supported by electrification and defense modernization trends, near-term profitability is expected to remain pressured as the company ramps up new product production and implements manufacturing efficiency improvements at its Newark, NY facility.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0020%

Operational disruptions at key facilities persist, and raw material cost volatility (lithium, cobalt) intensifies, further compressing gross margins. Delays in government and defense contract awards lead to backlog stagnation, resulting in continued quarterly net losses and downward pressure on the stock price.

Base CaseCentral scenario

$7.0050%

Ultralife gradually resolves its operational bottlenecks and plant disruptions over the next two quarters. Revenue growth stabilizes in the mid-single digits, supported by steady backlog conversion. Gross margins recover slowly, constrained by residual wage and utility inflation, keeping full-year earnings near break-even.

Bull CaseUpside scenario

$12.5030%

Rapid resolution of manufacturing inefficiencies and successful ramp-up of new high-energy battery products drive gross margins back toward historical mid-20% levels. Strong execution on the record $115.1 million backlog, combined with accelerated defense procurement cycles, leads to significant revenue outperformance and a return to profitability in the second half of 2026.

Scenarios reflect our research view at the research date.

Key Investment Merits

Record order backlog of $115.1 million provides strong revenue visibility and indicates robust underlying demand.
Strong market position in critical niches, including defense/government communications and high-reliability medical power solutions.
Ongoing vertical integration and consolidation under a single master brand to drive long-term operational efficiencies.

Key Investment Risks

Near-term margin pressure from production disruptions, higher utility costs, and non-recurring consulting/litigation expenses.
Exposure to raw material price volatility (lithium, cobalt, nickel) and supply chain constraints.
High concentration of government and defense revenue, making the company vulnerable to federal budget cycles and order timing.

Thesis Invalidation Triggers

A sustained decline in the order backlog below $90 million, indicating softening demand.
Failure of gross margins to recover above 22% by Q4 2026, signaling permanent structural cost increases.
Loss of key Tier-1 defense or medical OEM contracts.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.